Related Experiment Video
Updated: May 8, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
PARP1-specific inhibitor displays PARP1-detrapping activity
Kira Schützenhofer1, Ellen Laker1, Kyle Tsang1
1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.
Abstract:
The successful use of PARP inhibitors against primarily homologous recombination-deficient tumors relies on their ability to inhibit the catalytic activity of PARP1 and PARP2, leading to their retention at sites of DNA damage, known as PARP "trapping." Different PARP inhibitors vary in their trapping ability and thus in their resulting toxicity. Here, we develop an inducible complementation system for the expression of tagged PARP1 variants to assess the impact of different mutations in the PARP1 catalytic site on ADP-ribosylation (ADPr) activity, trapping, and cell survival. Testing these cell lines for their behavior and sensitivity to different PARP inhibitors, we find that saruparib, a first-in-class PARP1-specific inhibitor, promotes the release of certain PARP1 catalytic mutants and resistance to this inhibitor. We also characterize a PARP1 catalytic mutant with intact mono(ADP-ribosyl)ation activity but devoid of poly(ADP-ribosyl)ation, enabling us to demonstrate a significant contribution of mono(ADP-ribosyl)ation toward PARP1 release from sites of DNA damage.
Insights
PARP inhibitors trap PARP1/2 at DNA damage sites, but mutations affect trapping and drug response. This study reveals how specific PARP1 catalytic mutations impact trapping, ADP-ribosylation activity, and sensitivity to PARP inhibitors like saruparib.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- PARP inhibitors are effective against homologous recombination-deficient tumors by inhibiting PARP1 and PARP2.
- PARP inhibitor efficacy depends on their ability to trap PARP enzymes at DNA damage sites.
- Variations in PARP inhibitor trapping ability influence their toxicity.
Purpose of the Study:
- To investigate the impact of PARP1 catalytic site mutations on its ADP-ribosylation activity, DNA damage trapping, and cellular response to PARP inhibitors.
- To develop an inducible complementation system for studying PARP1 variants.
Main Methods:
- Developed an inducible complementation system for expressing tagged PARP1 variants.
- Assessed ADP-ribosylation activity, PARP trapping, and cell survival of PARP1 mutant cell lines.
- Tested cell line sensitivity to various PARP inhibitors, including saruparib.
Main Results:
- Certain PARP1 catalytic mutants showed altered ADP-ribosylation activity and trapping.
- Saruparib, a PARP1-specific inhibitor, induced release of specific PARP1 catalytic mutants, leading to resistance.
- Identified a PARP1 mutant with intact mono(ADP-ribosyl)ation but lacking poly(ADP-ribosyl)ation, demonstrating mono(ADP-ribosyl)ation's role in PARP1 release.
Conclusions:
- PARP1 catalytic site mutations significantly influence PARP trapping and cellular response to PARP inhibitors.
- Mono(ADP-ribosyl)ation plays a crucial role in the release of PARP1 from DNA damage sites.
- Understanding these mechanisms can inform the development of more effective PARP inhibitor therapies.
Related Concept Videos
Restarting Stalled Replication Forks
Long-patch Base Excision Repair
DNA Damage can Stall the Cell Cycle
